Endo oxymorphone “approvable”
Executive Summary
Endo oxymorphone opioid agonist extended-release and immediate-release tablets "approvable" at FDA. The agency requested that Endo provide additional information, "including some form of additional clinical trials to further confirm the safety and efficacy of these products," Endo says. The NDAs were filed Feb. 19...